Dr. Michael Palfreyman reports
CYBIN PRESENTS CYB003 PRECLINICAL DATA AT 2022 AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING
Cybin Inc. today presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (ACNP) annual meeting taking place Dec. 4 to Dec. 7, 2022, in Phoenix, Ariz. The data presented, including new pharmacokinetics (PK) findings, further strengthen the therapeutic profile of CYB003 as a novel treatment for major depressive disorder (MDD).
"These new findings demonstrate the unique PK properties of CYB003 compared with classical psilocybin and further supports our ongoing first-in-human phase 1/2a clinical trial evaluating CYB003 for the treatment of MDD," said Amir Inamdar, MBBS, DNB (psych), MFPM, Cybin's chief medical officer. "We were honoured to present our data at ACNP amongst leading scientists and academics in neuropsychopharmacology."
"Compared to classical psilocybin, CYB003 has demonstrated less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability. The potential therapeutic benefits of this molecule could result in shorter treatment time and reduce the resource burden on the health care system," said Michael Palfreyman, PhD, Cybin's chief research and development officer.
Poster 1 details:
Title: In Vitro and in Vivo Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder;
Authors: Michael Palfreyman, Joan Krakowsky, Michael Morgan, Clinton Canal, Pradip Pathare, Ken Avery, Amy Reichelt, Joshua Hartsel, Alex Nivorozhkin, Amir Inamdar and Geoffrey Varty;
Poster session: M111.
Poster 2 details:
Title: Pharmacokinetic Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder;
Authors: Amir Inamdar, Michael Morgan, Joan Krakowsky, Amy Reichelt, Clinton Canal, Tina Mueller, Ken Avery, Pradip Pathare, Joshua Hartsel, Alex Nivorozhkin, Geoffrey Varty and Michael Palfreyman;
Poster session: M112.
CYB003 is derived from psilocybin, which is part of a family of molecules called indolamines that include more common neurotransmitters, such as serotonin. Psilocybin is dephosphorylated to form its metabolite, psilocin, which can cross the blood-brain-barrier. Given its structural similarity to serotonin, psilocin can easily activate the serotonin 5-HT2A receptor. CYB003 is a deuterated psilocybin analog designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability for an overall better outcome for patients. CYB003 is currently being evaluated in a phase 1/2a clinical trial for the treatment of major depressive disorder.
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.